HK1035724A1 - Compounds as selective agonists at alpha 2B or 2B/2C adrenergic receptors. - Google Patents

Compounds as selective agonists at alpha 2B or 2B/2C adrenergic receptors.

Info

Publication number
HK1035724A1
HK1035724A1 HK01106343A HK01106343A HK1035724A1 HK 1035724 A1 HK1035724 A1 HK 1035724A1 HK 01106343 A HK01106343 A HK 01106343A HK 01106343 A HK01106343 A HK 01106343A HK 1035724 A1 HK1035724 A1 HK 1035724A1
Authority
HK
Hong Kong
Prior art keywords
alpha
compounds
selective agonists
adrenergic receptors
lower alkyl
Prior art date
Application number
HK01106343A
Other languages
English (en)
Inventor
Ken Chow
Daniel W Gil
James A Burke
Dale A Harcourt
Michael E Garst
Larry A Wheeler
Stephen A Munk
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1035724A1 publication Critical patent/HK1035724A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/28—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK01106343A 1999-06-10 2001-09-07 Compounds as selective agonists at alpha 2B or 2B/2C adrenergic receptors. HK1035724A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32975299A 1999-06-10 1999-06-10
PCT/US2000/015795 WO2001000586A1 (en) 1999-06-10 2000-06-08 Compounds as selective agonists at alpha 2b or 2b/2c adrenergic receptors

Publications (1)

Publication Number Publication Date
HK1035724A1 true HK1035724A1 (en) 2001-12-07

Family

ID=23286854

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106343A HK1035724A1 (en) 1999-06-10 2001-09-07 Compounds as selective agonists at alpha 2B or 2B/2C adrenergic receptors.

Country Status (11)

Country Link
EP (1) EP1104407B1 (cs)
AT (1) ATE283843T1 (cs)
AU (1) AU773668B2 (cs)
CZ (1) CZ2001864A3 (cs)
DE (1) DE60016359T2 (cs)
ES (1) ES2228544T3 (cs)
HK (1) HK1035724A1 (cs)
HU (1) HUP0104390A3 (cs)
RU (1) RU2232154C2 (cs)
TW (1) TWI283669B (cs)
WO (1) WO2001000586A1 (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254265B2 (en) * 1997-12-04 2008-05-15 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2B or 2B/2C adrenergic receptors
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
US6534542B2 (en) 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US20070042951A1 (en) * 2003-10-08 2007-02-22 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
US7632831B2 (en) * 2004-05-07 2009-12-15 Memory Pharmaceuticals Corporation 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
CA2581828A1 (en) 2004-09-24 2006-04-06 Allergan, Inc. 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
EP1791833A2 (en) 2004-09-24 2007-06-06 Allergan, Inc. 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
BRPI0516083A (pt) 2004-09-24 2008-08-19 Allergan Sales Inc 4-(fenilmetil e 4-fenilmetil substituìdo)-imidazol-2-tionas que atuam como agonistas alfa2 adrenérgicos
WO2006036512A2 (en) 2004-09-28 2006-04-06 Allergan, Inc. Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
US7390829B2 (en) 2005-06-29 2008-06-24 Allergan, Inc. Alpha-2 adrenergic agonists
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
WO2007024949A2 (en) * 2005-08-25 2007-03-01 Schering Corporation Alpha2c adrenoreceptor agonists
AR056043A1 (es) * 2005-08-25 2007-09-12 Schering Corp Agonistas de receptores adrenergicos alfa2c funcionalmente selectivos
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
US7592362B2 (en) 2006-01-19 2009-09-22 Pfizer Limited Substituted imidazoles
US7323477B2 (en) * 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
CA2669112A1 (en) * 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
US8013169B2 (en) 2007-01-12 2011-09-06 Allergan, Inc Naphthylmethylimidizoles as therapeutic agents
WO2008088936A1 (en) 2007-01-12 2008-07-24 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
WO2008088937A1 (en) 2007-01-12 2008-07-24 Allergan, Inc. Quinolynylmethylimidizoles as therapeutic agents
CL2008000430A1 (es) 2007-02-13 2008-08-18 Schering Corp Pharmacopeia Inc Compuestos derivados de heterociclos condensados sustituidos; composicion farmaceutica que comprende a dichos compuestos, utiles para el tratamiento de una o mas condiciones asociadas con receptores adrenergicos a2c, tales como congestion asociada a
EP2398776A1 (en) 2007-02-13 2011-12-28 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
JP2010518161A (ja) 2007-02-13 2010-05-27 シェーリング コーポレイション 機能選択性α２Ｃアドレナリン受容体アゴニストとしてのクロマン誘導体および類似体
AU2008251324B2 (en) * 2007-05-14 2014-05-01 Allergan, Inc. ((Phenyl)imidazolyl)methylheteroaryl compounds
CN101821254B (zh) * 2007-08-15 2013-10-09 阿勒根公司 肾上腺素能化合物
US7902247B2 (en) * 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
WO2009091735A1 (en) * 2008-01-18 2009-07-23 Allergan.Inc Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
US8383818B2 (en) 2008-02-21 2013-02-26 Merck Sharp & Dohme Corp. Functionally selective alpha2C adrenoreceptor agonists
WO2010042473A1 (en) 2008-10-07 2010-04-15 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
CN111372576A (zh) 2017-11-17 2020-07-03 塞尔利克斯生物私人有限公司 用于治疗眼部病症的组合物和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
JPH01242571A (ja) * 1988-03-22 1989-09-27 Mitsui Petrochem Ind Ltd イミダゾール誘導体の製造方法
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US5621113A (en) * 1996-03-28 1997-04-15 Ortho Pharmaceutical Corporation 4-[(thien-2-yl)methyl]-imidazole analgesics
US5750720A (en) * 1996-03-28 1998-05-12 Ortho Pharmaceutical Corporation 4- (thien-3-yl)methyl!-imidazole analgesics
ES2218853T3 (es) * 1997-10-02 2004-11-16 Daiichi Pharmaceutical Co., Ltd. Nuevos compuestos de dihidronaftaleno y procesos para la obtencion de los mismos.
ATE266643T1 (de) * 1997-12-04 2004-05-15 Allergan Inc Substituierte imidazole derivate mit agonistischähnlicher wirkung auf die alpha 2b oder 2b/2c adrenergischen rezeptoren

Also Published As

Publication number Publication date
DE60016359T2 (de) 2005-12-01
HUP0104390A2 (hu) 2002-04-29
EP1104407B1 (en) 2004-12-01
AU5474900A (en) 2001-01-31
TWI283669B (en) 2007-07-11
WO2001000586A1 (en) 2001-01-04
DE60016359D1 (de) 2005-01-05
ES2228544T3 (es) 2005-04-16
EP1104407A1 (en) 2001-06-06
HUP0104390A3 (en) 2002-05-28
RU2232154C2 (ru) 2004-07-10
CZ2001864A3 (cs) 2001-09-12
AU773668B2 (en) 2004-06-03
ATE283843T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
HK1035724A1 (en) Compounds as selective agonists at alpha 2B or 2B/2C adrenergic receptors.
CY1114120T1 (el) Αγωνιστες των βητα-2αδρενεργικων υποδοχεων
BR0213911A (pt) Análogos de Èmega-cicloalquil 17-heteroaril prostaglandina e2 como agonistas do receptor ep2
DK1309544T3 (da) Forbindelser, der virker som melanocortinreceptorligander
AR018917A1 (es) Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen.
DK0841922T3 (da) 1H-4(5)-substituerede imidazolderivater
MXPA04006281A (es) Analogos de tetrahidroquinolina como agonistas muscarinicos.
KR960704884A (ko) 항종양제 또는 항바이러스제로서의 디스타마이신 A 동족체 (Distamycin A analogues as antitumour or antiviral agents)
BR0007864A (pt) Composto, e, uso de um composto
CA2221110A1 (en) Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
DE69722592D1 (de) Histamin h 3 rezeptorliganden
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
AU2003294092A1 (en) Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics
EA200200727A1 (ru) Новые производные индола
BG105862A (en) Light, extruded compositions containing a light, extrudable, ceramic carrier, methods for their use and preparartion
PT1282617E (pt) Derivados de hidantoína com afinidade para os receptores da somatostatina
DE60031676D1 (en) N-cyclopentylmodulatoren der chemokine rezeptoraktivität
ATE477263T1 (de) Zusammensetzung enthaltend ferrocen-derivate und treibstoff diese enthaltend
ES2170802T3 (es) Carboxamidas biciclicas como ligandos de los receptores 5-ht1a.
ES2168062A1 (es) Composiciones para control de cucarachas
DK1165584T3 (da) 2'-substitueret RNA fremstilling
PT923576E (pt) Derivados de 4-amino-etoxi-indolona como agonistas de dopamina d2
KR960022511A (ko) 2-(4'-티아졸릴)벤즈이미다졸의 제조방법
CO5180593A1 (es) Compuestos heterociclos 4-bencilpiperidina alquilsulfoxidos y su uso como antagonistas receptores de subtipo selectivo de n-metil-aspartato

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090608